Is Egrifta (Tesamorelin) Legal in Maryland? How to Access It Legally

HealthRX.com

Egrifta is FDA-approved, but only for HIV lipodystrophy

Print or save as PDF

See the public record for Tesamorelin

  • Drug / Tesamorelin (Egrifta SV, Egrifta WR)
  • FDA status / First approved November 10, 2010, application BLA 022505 [4]
  • Approved use / Excess abdominal fat in HIV-infected adults with lipodystrophy [1][2]
  • Not approved for / Weight loss; the label calls the effect weight neutral [1]
  • Dose / Egrifta SV 1.4 mg once daily; Egrifta WR 1.28 mg once daily; not substitutable [1][2]
  • Maryland / A person may not practice medicine in the state unless licensed by the Board [3]
  • Compounded form / Not FDA-approved; FDA does not review compounded drugs before marketing [5][6]

What the federal status is

Egrifta was first approved on November 10, 2010, under BLA 022505 [4]. The current labels are Egrifta SV, a 2 mg vial, and Egrifta WR, an 11.6 mg vial; both are once-daily subcutaneous injections into the abdomen, and both labels are dated July 29, 2026 [1][2].

The approved use is narrow. Both labels state tesamorelin is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. Both add the same limits: long-term cardiovascular safety has not been established; the risk/benefit of continuing should be considered in patients who have not had a reduction in visceral adipose tissue; and the drug is not indicated for weight loss management because its effect on weight is neutral [1][2]. Use in someone without HIV lipodystrophy sits outside the approved use [1].

Maryland rules: what the statute says

Health Occupations §14–601 says a person may not practice, attempt to practice or offer to practice medicine in the state unless licensed by the Board [3]. That is a general licensing rule for the practice of medicine; it does not mention tesamorelin.

Questions worth asking

Choose the questions you want to keep

Is compounded tesamorelin FDA-approved?

No. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [5][6]. Tesamorelin is not on FDA's page of bulk substances that may present significant safety risks when compounded, and it appears in no category of FDA's lists for state-licensed pharmacies and physicians or for outsourcing facilities [7][8][9]. It is also a component of an FDA-approved drug, Egrifta [4].

What the label says about who should not use it

Both labels contraindicate tesamorelin in people with disruption of the hypothalamic-pituitary axis (hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation or head trauma), active malignancy, known hypersensitivity to tesamorelin or its excipients, and pregnancy [1][2]. The labels direct prescribers to monitor IGF-1, because tesamorelin raises it: among patients treated 26 weeks, 47% had IGF-1 above 2 SDS and 36% above 3 SDS [1]. They also direct glucose monitoring: HbA1c of 6.5% or higher developed in 5% of tesamorelin patients versus 1% on placebo by week 26 [1].

Egrifta SV and Egrifta WR are not interchangeable

Egrifta SV is 1.4 mg (0.35 mL of the reconstituted solution) once daily, mixed only with the supplied Sterile Water for Injection and given immediately, with the remainder discarded [1]. Egrifta WR is 1.28 mg (0.16 mL) once daily, mixed with 1.3 mL of Bacteriostatic Water for Injection; one vial supplies seven daily doses and is discarded seven days after mixing [2]. The WR label states the two are not substitutable [2].

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. Which statement about compounded tesamorelin is correct, according to the article?

Question 1 of 3

Score: 0 right, 0 of 3 answered

Is tesamorelin legal in Maryland?
Yes. Tesamorelin is an FDA-approved prescription product, sold as Egrifta SV and Egrifta WR [1][2][4]. Maryland law says a person may not practice medicine in the state unless licensed by the Board [3].
What is Egrifta approved to treat?
Reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. The label says it is not indicated for weight loss management as it has a weight-neutral effect [1][2].
Are Egrifta SV and Egrifta WR interchangeable?
No. Egrifta SV is 1.4 mg once daily and Egrifta WR is 1.28 mg once daily, and the WR label states the two formulations are not substitutable [1][2].
Is compounded tesamorelin FDA-approved?
No. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [5][6].
Show all 9 referencesHide references
  1. U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
  2. U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
  3. Laws - Statute Text.
  4. Drugs@FDA: FDA-Approved Drugs.
  5. Official web page.
  6. Official web page.
  7. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  8. U.S. Food and Drug Administration.
  9. U.S. Food and Drug Administration.
Evidence overview for Is Egrifta (Tesamorelin) Legal in Maryland? How to Access It Legally